These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33798825)

  • 1. Increased platelet glycoprotein IIb/IIIa activation precedes continuous-flow left ventricular assist device pump thrombosis events.
    Weiland M; Schuitema J; Jovinge S; Lee S
    Thromb Res; 2021 May; 201():143-146. PubMed ID: 33798825
    [No Abstract]   [Full Text] [Related]  

  • 2. Left ventricular assist device pump thrombosis: is there a role for glycoprotein IIb/IIIa inhibitors?
    Bellumkonda L; Subrahmanyan L; Jacoby D; Bonde P
    ASAIO J; 2014; 60(1):134-6. PubMed ID: 24335386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis in continuous-flow left ventricular assist devices: pathophysiology, prevention, and pharmacologic management.
    Jennings DL; Weeks PA
    Pharmacotherapy; 2015 Jan; 35(1):79-98. PubMed ID: 25329333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of a continuous flow left ventricular assist device thrombosis with eptifibatide.
    Jennings DL; Cabrera R; Wang DD; Tita C
    ASAIO J; 2012; 58(6):633-5. PubMed ID: 23103702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding.
    Chen Z; Zhang J; Kareem K; Tran D; Conway RG; Arias K; Griffith BP; Wu ZJ
    Artif Organs; 2019 Aug; 43(8):745-755. PubMed ID: 30805954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profound thrombocytopenia with glycoprotein IIb/IIIa inhibitors plus heparin for pump thrombus.
    Blais DM; Sun B; Vesco P; Louis LB; Sai-Sudhakar C; Firstenberg MS
    J Heart Lung Transplant; 2008 Dec; 27(12):1361-2. PubMed ID: 19059120
    [No Abstract]   [Full Text] [Related]  

  • 7. Local glycoprotein IIb/IIIa receptor inhibitor delivery from the pump surface attenuates platelet adhesion in continuous flow ventricular assist devices.
    Linneweber J; Dohmen PM; Kertzscher U; Affeld K; Konertz W
    Artif Organs; 2008 Oct; 32(10):792-9. PubMed ID: 18959668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Various Treatment Strategies for Patients with Continuous-Flow Ventricular Assist Device Thrombosis: A Retrospective Analysis.
    Ertugay S; Engin C; Daylan A; Pektok E; Ozturk P; Nalbantgil S; Zoghi M; Yagdi T; Ozbaran M
    ASAIO J; 2016; 62(5):533-8. PubMed ID: 27258228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Thomas MD; Wood C; Lovett M; Dembo L; O'Driscoll G
    J Heart Lung Transplant; 2008 Aug; 27(8):925-7. PubMed ID: 18656810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pump Thrombosis: A Limitation of Contemporary Left Ventricular Assist Devices.
    Kapur NK; Vest AR; Cook J; Kiernan MS
    Curr Probl Cardiol; 2015 Dec; 40(12):511-40. PubMed ID: 26542611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices.
    Tellor BR; Smith JR; Prasad SM; Joseph SM; Silvestry SC
    J Heart Lung Transplant; 2014 Jan; 33(1):94-101. PubMed ID: 24418735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication management for left ventricular assist device thrombosis.
    Hohner E; Crow J; Moranville MP
    Am J Health Syst Pharm; 2015 Jul; 72(13):1104-13. PubMed ID: 26092961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirofiban in Suspected Left Ventricular Assist Device Pump Thrombosis.
    Nei SD; Wieruszewski PM; Orzel LA; Ritchie BM; Stulak JM
    ASAIO J; 2020 Aug; 66(8):886-889. PubMed ID: 32740348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa inhibitor attenuates complement activation during in vitro ventricular assist circulation.
    Serna DL; Huh J; Ha H; Parhizgar SS; Chen JC
    ASAIO J; 1998; 44(5):M352-5. PubMed ID: 9804451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.
    Ray MJ; Juneja M; Bett N; Walters DL
    EuroIntervention; 2009 Aug; 5(3):330-5. PubMed ID: 19736157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology.
    Rossi ML; Zavalloni D
    Mini Rev Med Chem; 2004 Sep; 4(7):703-9. PubMed ID: 15379638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for selective degradation of platelet GP IIb/IIIa complex after prolonged in vitro ventricular assist.
    Serna DL; King BO; Huh J; Jalal R; Tran L; Chen JC
    J Investig Med; 1998 Aug; 46(6):279-83. PubMed ID: 9737089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.
    Nurden AT; Poujol C; Durrieu-Jais C; Nurden P
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2835-40. PubMed ID: 10591658
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine.
    Chen Y; Ju LA
    Stroke Vasc Neurol; 2020 Jun; 5(2):185-197. PubMed ID: 32606086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.